Zenas Biopharma (ZBIO) Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The current EV/EBITDA multiple of Zenas Biopharma Inc (ZBIO) is subject to geopolitical risks and the complexity of patent protection. The value 0.00 represents the current metric, while the pricing potential of Zenas Biopharma Inc (ZBIO) depends on the efficacy of new molecules. The company's strategy relies on the expansion of bifunctional antibodies for the therapy of severe autoimmune pathologies in early stages.
Zenas Biopharma - analytical breakdowns and key metrics (ZBIO)
- current price and projected stock value:
- market capitalization details:
- book value of equity indicators:
- debt level and financial liquidity data:
- business earnings and investment ratios data:
ZBIO - Company Profit|Projected Future Earnings Zenas Biopharma Inc|ZBIO - P/E Multiple|Future Price to Earnings Zenas Bio|ZBIO - Growth-Adjusted Market Cap to Net Income|Enterprise Value to EBITDA Ratio Zenas Bio|ZBIO - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) Zenas Biopharma|ZBIO - Earnings per share for the last twelve months|Quarterly EPS earnings growth zenasbio.com|ZBIO - Expected net earnings per share growth this year|Net earnings per share growth forecast for next year Zenas Biopharma Inc
- sales and revenue data:
Initial company analysis:Zenas Biopharma, Inc. (ZBIO)
Zenas Biopharma Inc (ZBIO) is mitigating drug development failure risks by diversifying its clinical pipeline, establishing a foundation for stable capitalization. The enterprise value to EBITDA (EV/EBITDA) ratio enables an assessment of this asset accounting for debt and taxes, which clearly demonstrates the business valuation via EV/EBITDA trends within the context of market consensus and US economic expansion phases.
Direct competitors
EV/EBITDA Multiple ARGX (argenx.com)|Total Company Value to Operating Income Before Depreciation Ratio biontech.de (BNTX)|ABVX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ADMA Biologics Inc (ADMA) - Enterprise Value to EBITDA Ratio|Protagonist Corp (PTGX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio Immunovant, Inc.|Enterprise Value to EBITDA Ratio KNSA|EV/EBITDA Multiple grifols.com|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Adaptive Biotechnologies Corp (ADPT)|Celldex Therapeutics, Inc. - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple AUPH (auriniapharma.com)|BioCryst Pharmaceuticals Inc (BCRX) - Company Value to EBITDA|VERA: Enterprise Value to EBITDA Ratio|DNTH (Dianthus Therapeutics) - Enterprise Value to Operating Income Before Depreciation|PHVS: EV/EBITDA Multiple|ABCL (AbCellera Biologics Inc.) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio TRML|Company Value to EBITDA Intrexon PGEN|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Pharming Group N.V. (PHAR)|Enterprise Value to Operating Income Before Depreciation Ratio NKTR|EV/EBITDA Multiple UPB (Upstream Pharma)|IMNM: Enterprise Value to Operating Income Before Depreciation|GOSS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio KalVista Pharmaceuticals KALV|Septerna (SEPN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|pieris.com - Business Value to Operating Income Before Depreciation|SVRA (Savara Inc) - EV/EBITDA Multiple|RIGL: Business Value to Operating Income Before Depreciation|EV/EBITDA Multiple ANAB|ATXS (Astria Pharma) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization enGene Holdings Inc. ENGN|EV/EBITDA Multiple RAPT Therapeutics Inc. RAPT|Aerovate Therapeutics - EV/EBITDA Multiple|Company Value to EBITDA Aclaris Therapeutics Inc.|Kyverna (KYTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Company Value to EBITDA Tiziana Life Sciences (TLSA)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cabaletta Bio Inc.|Ventyx Biosciences (VTYX) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple THTX|EV/EBITDA Multiple Avalo Therapeutics Inc. (AVTX)|EV/EBITDA Multiple ELDN (eledon.com)|AGEN - Enterprise Value to EBITDA Ratio|CLYM: Enterprise Value to EBITDA Ratio|ZURA (Zura Bio Limited) - Enterprise Value to Operating Income Before Depreciation|ATYR: EV/EBITDA Multiple|Adagene (ADAG) - EV/EBITDA Multiple|IMA (ikenaoncology.com) - EV/EBITDA Multiple|shattucklabs.com (STTK) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Equillium Inc (EQ)|Connect Pharma - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Immunic, Inc. IMUX|ATRA - Enterprise Value to EBITDA Ratio|IFRX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|XFOR: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|ACET: EV/EBITDA Multiple|Celularity Corp (CELU) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization INmune Bio|Barinthus Biotherapeutics plc (BRNS) - Total Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple KZR|SABS: Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple AKTX (Akari Therapeutics, Plc)|ENLV (Enlivex Therapeutics, Ltd.) - Company Value to Operating Income Before Depreciation Ratio|QTTB: Enterprise Value to EBITDA Ratio|GOVX - EV/EBITDA Multiple|Edesa Biotech Corp (EDSA) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|IBIO - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization carismatx.com|XTLB: Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Bolt Biotherapeutics Inc. (BOLT)|HCWB (HCW Biologics) - Business Value to Operating Income Before Depreciation|Aptevo Therapeutics - Enterprise Value to EBITDA Ratio|EV/EBITDA Multiple AIM ImmunoTech Inc. AIM|Aditxt Inc. - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation GRI (GRI Bio, Inc.)|XORTX Therapeutics Inc (XRTX) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to EBITDA Ratio ReShape Lifesciences|Enterprise Value to EBITDA Ratio REVB|Indaptus Corp (INDP) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization scinai.com (SCNI)|Enterprise Value to EBITDA Ratio CalciMedica CALI|EV/EBITDA Multiple AFMD (affimed.com)|Allakos Inc. (ALLK) - Company Value to EBITDA|HOOKIPA - EV/EBITDA Multiple|IGMS (igmbio.com) - Enterprise Value to Operating Income Before Depreciation|ITOS (iTeos) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation OCEA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization TC BioPharm|Third Harmonic Bio Inc. (THRD) - Total Company Value to Operating Income Before Depreciation Ratio
